Mammoth Biosciences
-
Pfizer, Bayer each strike up deals to add in-vivo gene editing to pipeline mix
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
-
Mammoth Bio’s massive $195M financing makes the CRISPR company a unicorn
Mammoth Biosciences is applying CRISPR technology to both diagnostics and therapeutics. With the new financing, CEO Trevor Martin said that the company is looking ahead toward clinical trials and perhaps partnerships with larger companies.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Mammoth Biosciences, GSK partner on CRISPR-based Covid-19 diagnostic
The companies plan to apply with the Food and Drug Administration for an emergency use authorization by the end of the year. Mammoth’s technology is based on the research of CRISPR pioneer Jennifer Doudna.
-
Mammoth Biosciences raises $45M Series B round for CRISPR diagnostics, therapeutics development
The latest round of funding, led by Chinese investors, brings the total amount of money raised by the company, co-founded by CRISPR pioneer Jennifer Doudna, to more than $70 million.